

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,  
INC., WATSON LABORATORIES, INC., DR. REDDY'S LABORATORIES,  
INC., DR. REDDY'S LABORATORIES, LTD., and SUN  
PHARMACEUTICALS INDUSTRIES LTD.

Petitioner,

v.

MERCK SHARP & DOHME CORP.  
Patent Owner.

---

Case IPR2020-00040

U.S. Patent 7,326,708 B2

---

**MYLAN'S NOTICE OF DEPOSITION OF  
KARL B. HANSEN, Ph.D.**

Pursuant to 37 C.F.R. § 42.53, prior agreement with counsel for Patent Owner Merck Sharp & Dohme Corp., and subject to further modification of the case schedule as authorized by the Board, Petitioner Mylan Pharmaceuticals Inc., by and through its attorneys, will conduct the cross-examination by deposition of Karl B. Hansen, Ph.D., on Thursday October 8, 2020. The deposition will be conducted by videoconference and will commence at 9:00 a.m., Eastern Time, or such time as the parties agree. The deposition shall be taken before a duly authorized notary public or other officer authorized to administer oaths and will be recorded by audiotape, videotape, and/or stenographic means.

Date: September 21, 2020

Respectfully submitted,

/s Jitendra Malik/

Jitendra Malik, Ph.D. (Reg. No. 55,823)

Alissa M. Pacchioli (Reg. No. 74,252)

Christopher W. West, Ph.D.

(Reg. No. 74,724)

Heike S. Radeke, Ph.D.

(Reg. No. 75,394)

Lance Soderstrom (Reg. No.65,405)

KATTEN MUCHIN ROSENMAN

550 S. Tryon Street, Suite 2900

Charlotte, NC 28202-4213

jitty.malik@katten.com

alissa.pacchioli@katten.com

christopher.west@katten.com

heike.radeke@katten.com

lance.soderstrom@katten.com

*Counsel for Petitioner*

*Mylan Pharmaceuticals Inc.*

**CERTIFICATION UNDER 37 C.F.R. § 42.24(d)**

Pursuant to 37 C.F.R. 42.6(e), the undersigned hereby certifies that a true and correct copy of the foregoing was served on September 21, 2020, by delivering a copy via electronic mail on the following attorneys of record.

[sfisher@wc.com](mailto:sfisher@wc.com)

[jberniker@wc.com](mailto:jberniker@wc.com)

[smahaffy@wc.com](mailto:smahaffy@wc.com)

[asheh@wc.com](mailto:asheh@wc.com)

[bgenderson@wc.com](mailto:bgenderson@wc.com)

[ebaumgarten@wc.com](mailto:ebaumgarten@wc.com)

[azolan@wc.com](mailto:azolan@wc.com)

[kzullow@goodwinprocter.com](mailto:kzullow@goodwinprocter.com)

[sfischer@goodwinprocter.com](mailto:sfischer@goodwinprocter.com)

[jwong@winston.com](mailto:jwong@winston.com)

[ZCohen@winston.com](mailto:ZCohen@winston.com)

[CKlein@winston.com](mailto:CKlein@winston.com)

[Cfundakowski@winston.com](mailto:Cfundakowski@winston.com)

[rfaegenburg@lerner david.com](mailto:rfaegenburg@lerner david.com)

[tvanbuskirk@lerner david.com](mailto:tvanbuskirk@lerner david.com)

[mteschner@lerner david.com](mailto:mteschner@lerner david.com)

[ERapalino@goodwinlaw.com](mailto:ERapalino@goodwinlaw.com)

*/s Jitendra Malik/*

Jitendra Malik, Ph.D. (Reg. No. 55,823)